Genentech, a member of the Roche Group, announced that people with HER2-positive metastatic breast cancer, or mBC, lived significantly longer - overall survival - when treated with the combination of Perjeta, or pertuzumab, Herceptin, or trastuzumab, and docetaxel chemotherapy, compared to Herceptin and docetaxel chemotherapy alone in the Phase III CLEOPATRA study. These data will be submitted for presentation at an upcoming medical meeting.
U.S. regulators are in the early stages of an antitrust probe into whether Google Inc, the top player in Web display …